View : 189 Download: 43
Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease
- Title
- Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease
- Authors
- Lee H.A.; Kim H.Y.
- Ewha Authors
- 김휘영; 이한아
- SCOPUS Author ID
- 김휘영; 이한아
- Issue Date
- 2023
- Journal Title
- International Journal of Molecular Sciences
- ISSN
- 1661-6596
- Citation
- International Journal of Molecular Sciences vol. 24, no. 11
- Keywords
- diabetes; liraglutide; nonalcoholic steatohepatitis; semaglutide; tirzepatide
- Publisher
- MDPI
- Indexed
- SCIE; SCOPUS
- Document Type
- Review
- Abstract
- Nonalcoholic fatty liver disease (NAFLD) can lead to liver fibrosis and cirrhosis. Recently, glucagon-like peptide 1 receptor agonists (GLP-1RAs), a class of drugs used to treat type 2 diabetes and obesity, have shown therapeutic effects against NAFLD. In addition to reducing blood glucose levels and body weight, GLP-1RAs are effective in improving the clinical, biochemical, and histological markers of hepatic steatosis, inflammation, and fibrosis in patients with NAFLD. Additionally, GLP-1RAs have a good safety profile with minor side effects, such as nausea and vomiting. Overall, GLP-1RAs show promise as a potential treatment for NAFLD, and further studies are required to determine their long-term safety and efficacy. © 2023 by the authors.
- DOI
- 10.3390/ijms24119324
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
-
ijms-24-09324.pdf(1.24 MB)
Download
- Export
- RIS (EndNote)
- XLS (Excel)
- XML